Search

Camille L Bedrosian

from San Rafael, CA
Age ~72
Get Report
Also known as:
Camille Dr Bedrosian, Camil Bedrosian, Agnes Bedrosian
Connected to:
Caroline R Bedrosian, 71Gasia Bedrosian, 42Mary E Bedrosian, 52Patricia A Bedrosian, 51Narine Bedrossian, 61Robert C Bedrossian, 72Ryan Bedrossian, 43Vasken M Bedrossian, 61Aso Bedroussian, 69Andrea M Bedsaul, 51

Camille Bedrosian Phones & Addresses

  • San Rafael, CA
  • Novato, CA
  • 41 Grouse Ln, Woodbridge, CT 06525 (203) 298-4035
  • Malvern, PA
  • 22 Lantern Rd, Belmont, MA 02478 (617) 484-1182
  • Durham, NC
  • 41 Grouse Ln, Woodbridge, CT 06525

Work

Position: Medical Professional

Education

School / High School: Harvard Medical School 1983

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 1986

Specialities

Internal Medicine

Professional Records

Medicine Doctors

Camille Bedrosian Photo 1

Dr. Camille L Bedrosian, Cheshire CT - MD (Doctor of Medicine)

View page
Specialties:
Internal Medicine
Address:
352 Knotter Dr, Cheshire, CT 06410
(203) 271-8393 (Phone)
Certifications:
Internal Medicine, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1983
Medical School
Newton-Wellesley Hosp
Graduated: 1983
Medical School
Duke University Hospital
Graduated: 1983
Camille Bedrosian Photo 2

Camille L Bedrosian

View page
Specialties:
Internal Medicine
Hematology & Oncology
Education:
Harvard University(1983)
Camille Bedrosian Photo 3

Camille Lucia Bedrosian, Cambridge MA

View page
Specialties:
Internist
Address:
26 Landsdowne St, Cambridge, MA 02139
Education:
Harvard Medical School - Doctor of Medicine
Duke University Hospital - Fellowship - Hematology and Oncology (Internal Medicine)
Duke University Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine

Business Records

Name / Title
Company / Classification
Phones & Addresses
Camille Lucia Bedrosian
Medical Doctor
ARIAD Pharmaceuticals, Inc.
Pharmaceuticals · Mfg Biological Products and Medical Research · Mfg of Biological Products & Medical Research · Mfg of Biological Products and Medical Research · Pharmaceutical Research Labora
26 Landsdowne St, Cambridge, MA 02139
Cambridge, MA 02139
(617) 494-0400, (617) 494-8144, (617) 494-9980
Camille Lucia Bedrosian
Medical Doctor, Owner
ARIAD CORPORATION
Researcher of Pharmaceutical Products · Pharmaceutical Preparation Mfg
26 Landsdowne St, Cambridge, MA 02139
(617) 494-0400, (617) 494-8144

Publications

Us Patents

Therapeutic Materials And Methods

View page
US Patent:
20060194829, Aug 31, 2006
Filed:
Dec 20, 2005
Appl. No.:
11/312296
Inventors:
Timothy Clackson - Arlington MA, US
Camille Bedrosian - Belmont MA, US
International Classification:
A61K 31/4745
A61K 31/4545
A61K 31/445
US Classification:
514291000, 514316000, 514317000
Abstract:
Disclosed are compositions and methods for treating or preventing mucositis by administering to the patient an FKBP ligand prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof, but in particular, administration of an mTOR inhibitor such as rapamycin, AP23573, CC1779 or everolimus.

Therapeutic Methods

View page
US Patent:
20070185150, Aug 9, 2007
Filed:
Nov 14, 2006
Appl. No.:
11/598850
Inventors:
Camille Bedrosian - Belmont MA, US
International Classification:
A61K 31/4353
US Classification:
514299000
Abstract:
Disclosed are methods for treating a patient with an mTOR inhibitor such as AP23573, sirolimus, temsirolimus, everolimus, etc.

Treatment Method

View page
US Patent:
20080081053, Apr 3, 2008
Filed:
Sep 30, 2005
Appl. No.:
11/663940
Inventors:
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 31/33
A61K 9/00
A61P 43/00
US Classification:
424400, 514183
Abstract:
A method for treating AML is disclosed which comprises administering an mTOR inhibitor to a patient in need thereof.

Therapeutic Materials And Methods

View page
US Patent:
20080207644, Aug 28, 2008
Filed:
Nov 27, 2007
Appl. No.:
11/986878
Inventors:
Stephen T. Sonis - Wayland MA, US
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 31/522
A61K 31/4965
A61K 31/454
A61P 35/00
US Classification:
51425506, 51426332, 514323
Abstract:
Disclosed are methods for treating various cancers. Methods encompass the administration of an mTOR inhibitor in combination with a second drug selected from an ImiD, a PDE4 inhibitor, a p38 MAP kinase inhibitor, a xanthine anticytokine, a dual TACE/MMP inhibitor and a proteasome inhibitor.The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the mTOR inhibitor.

Biomarkers For Evaluating Likelihood Of Tumor Sensitivity To An Mtor Inhibitor

View page
US Patent:
20090215812, Aug 27, 2009
Filed:
May 8, 2006
Appl. No.:
11/913964
Inventors:
Camille L. Bedrosian - Belmont MA, US
Timothy P. Clackson - Lexington MA, US
Victor Rivera - Arlington MA, US
Assignee:
ARIAD GENE THERAPEUTICS, INC. - Cambridge MA
International Classification:
A61K 31/436
C12Q 1/00
C12Q 1/68
G01N 33/53
US Classification:
514291, 435 4, 435 6, 435 71
Abstract:
The present invention provides compositions and methods for evaluating the likelihood that a tumor is sensitive to an mTOR inhibitor, e.g., rapamycin or a rapamycin analog. The invention provides FKBP proteins as biomarkers for predicting the likelihood that a tumor is sensitive to an mTOR inhibitor. The methods include assessing the expression or activity of an FKBP protein, e.g., FKBP 12, in a subject with a tumor or in a sample derived from a tumor. Additional biomarkers and biomarker combinations are also provided. The invention also provides kits containing, e.g., a validated antibody or ligand for assessing the expression or activity of an FKBP protein.

Capecitabine Combination Therapy

View page
US Patent:
20090311249, Dec 17, 2009
Filed:
Jun 4, 2007
Appl. No.:
12/227656
Inventors:
Luca Gianni - Milan, IT
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 39/395
A61P 35/00
A61K 31/506
US Classification:
4241331, 514274
Abstract:
The invention provides the use of a combination of an mTOR inhibitor and capecitabine in the treatment of cancer.

Combination Therapy

View page
US Patent:
20100266590, Oct 21, 2010
Filed:
Aug 1, 2007
Appl. No.:
12/309665
Inventors:
George D. Demetri - Brookline MA, US
Stephen T. Sonis - Wayland MA, US
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 39/395
A61P 35/00
A61P 35/02
US Classification:
4241341, 4241331, 4241421
Abstract:
Disclosed are methods for treating various cancers. Methods encompass the administration of a first drug such as AP23573, temsirolimus or everolimus in combination with a second drug selected from Remicade, Humira, Enbrel, Raptiva, Abatacept, Actermra, Cimzia or anakinra.The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the first drug.

Methods And Compositions For Treating Complement-Associated Disorders

View page
US Patent:
20120225056, Sep 6, 2012
Filed:
Nov 10, 2009
Appl. No.:
13/128523
Inventors:
Russell P. Rother - Oklahoma City OK, US
Camille Bedrosian - Woodbridge CT, US
Stephen P. Squinto - Bethany CT, US
Leonard Bell - Woodbridge CT, US
Assignee:
Alexion Pharmaceuticals, Inc. - Chesire CT
International Classification:
A61K 39/395
A61K 35/407
A61K 35/23
A61K 35/34
A61K 35/42
A61P 13/12
A61K 35/44
A61K 35/28
A61K 35/12
A61P 7/02
A61P 9/14
A61K 35/00
A61K 35/36
US Classification:
4241331, 424520, 424553, 424558, 424569, 424557, 424574, 424571, 424577, 4241581
Abstract:
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
Control profile
Camille L Bedrosian from San Rafael, CA, age ~72 Get Report